ATA106594A - Pharmazeutische orale zusammensetzung enthaltend verbindungen der rapamycinklasse - Google Patents

Pharmazeutische orale zusammensetzung enthaltend verbindungen der rapamycinklasse

Info

Publication number
ATA106594A
ATA106594A AT0106594A AT106594A ATA106594A AT A106594 A ATA106594 A AT A106594A AT 0106594 A AT0106594 A AT 0106594A AT 106594 A AT106594 A AT 106594A AT A106594 A ATA106594 A AT A106594A
Authority
AT
Austria
Prior art keywords
composition containing
oral composition
class compounds
pharmaceutical oral
containing rapamycin
Prior art date
Application number
AT0106594A
Other languages
English (en)
Other versions
AT408521B (de
Original Assignee
Novartis Erfind Verwalt Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939310974A external-priority patent/GB9310974D0/en
Priority claimed from GB939320463A external-priority patent/GB9320463D0/en
Application filed by Novartis Erfind Verwalt Gmbh filed Critical Novartis Erfind Verwalt Gmbh
Priority to AT172297A priority Critical patent/AT409082B/de
Priority to AT12282000A priority patent/AT408520B/de
Publication of ATA106594A publication Critical patent/ATA106594A/de
Application granted granted Critical
Publication of AT408521B publication Critical patent/AT408521B/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT0106594A 1993-05-27 1994-05-25 Pharmazeutische orale zusammensetzung enthaltend verbindungen der rapamycinklasse AT408521B (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AT172297A AT409082B (de) 1993-05-27 1997-10-13 Pharmazeutische orale zusammensetzung enthaltend fk506
AT12282000A AT408520B (de) 1993-05-27 2000-07-14 Galenische formulierungen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939310974A GB9310974D0 (en) 1993-05-27 1993-05-27 Organic compounds
GB939320463A GB9320463D0 (en) 1993-10-05 1993-10-05 Organic compounds

Publications (2)

Publication Number Publication Date
ATA106594A true ATA106594A (de) 2001-05-15
AT408521B AT408521B (de) 2001-12-27

Family

ID=26302958

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0106594A AT408521B (de) 1993-05-27 1994-05-25 Pharmazeutische orale zusammensetzung enthaltend verbindungen der rapamycinklasse

Country Status (10)

Country Link
US (4) US5932243A (de)
JP (3) JP3121203B2 (de)
AT (1) AT408521B (de)
BE (1) BE1008329A3 (de)
CA (1) CA2124259C (de)
CH (1) CH686761A5 (de)
DE (1) DE4418115B4 (de)
ES (1) ES2098180B1 (de)
FR (1) FR2705566B1 (de)
IT (1) IT1272992B (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
ATE398448T1 (de) 1993-09-28 2008-07-15 Scherer Gmbh R P Herstellung von weichgelatinekapseln
IL129547A (en) * 1994-10-26 2001-01-11 Novartis Ag Pharmaceutical compositions comprising a macrolide and an acid
US7205279B2 (en) * 1995-10-25 2007-04-17 Novartis Ag Pharmaceutical compositions
GB2308545B (en) * 1994-10-26 1999-06-02 Novartis Ag Pharmaceutical microemulsion preconcentrates
CN100335063C (zh) 1994-10-26 2007-09-05 诺瓦蒂斯有限公司 药物组合物
SK164796A3 (en) 1994-11-03 1997-06-04 Dresden Arzneimittel Novel cyclosporine preparation forms for oral administration of and process for producing them
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
US20050053594A1 (en) * 1995-11-16 2005-03-10 Dario Alessi RAC-PK as a therapeutic agent or in diagnostics, screening method for agents and process for activating RAC-PK
DE19544507B4 (de) * 1995-11-29 2007-11-15 Novartis Ag Cyclosporin enthaltende Präparate
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
US5858401A (en) * 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6465016B2 (en) * 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
CA2230748C (en) * 1997-03-14 2010-08-03 American Home Products Corporation Rapamycin formulations for oral administration
EP0978288A4 (de) * 1997-04-11 2006-07-12 Astellas Pharma Inc Medizinische zusammensetzung
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
US20070087028A1 (en) * 1998-04-16 2007-04-19 Robert Falotico Intraluminal devices for the prevention and treatment of vascular disease
KR100635456B1 (ko) 1998-05-29 2006-10-18 스키에파마 캐나다 인코포레이티드 열보호화 마이크로입자 조성물 및 그의 말단의 스팀멸균방법
DE69912441T2 (de) 1998-08-19 2004-08-19 Skyepharma Canada Inc., Verdun Injizierbare wässerige propofoldispersionen
IL143197A0 (en) 1998-11-20 2002-04-21 Rtp Pharma Inc Dispersible phospholipid stabilized microparticles
ATE404172T1 (de) 1998-12-30 2008-08-15 Dexcel Ltd Dispergierbares konzentrat zur verabreichung von cyclosporin
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
GB9912476D0 (en) * 1999-05-28 1999-07-28 Novartis Ag Organic compounds
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
WO2001028518A1 (de) * 1999-10-20 2001-04-26 Vesifact Ag Cyclosporine enthaltende mikroemulsion-prekonzentrate und mikroemulsionen
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US7300662B2 (en) 2000-05-12 2007-11-27 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US6623765B1 (en) * 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
ATE485837T1 (de) * 2000-08-03 2010-11-15 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
CA2424029C (en) 2000-09-29 2008-01-29 Cordis Corporation Coated medical devices
DE60133053T2 (de) 2000-10-16 2009-02-26 Conor Medsystems, Inc., Menlo Park Ausdehnbare medizinische Vorrichtung zur Abgabe eines nützlichen Agens
US7842083B2 (en) 2001-08-20 2010-11-30 Innovational Holdings, Llc. Expandable medical device with improved spatial distribution
SE0102993D0 (sv) * 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
IL160761A0 (en) 2001-10-19 2004-08-31 Isotechnika Inc Novel cyclosporin analog microemulsion preconcentrates
US20030217129A1 (en) * 2002-05-15 2003-11-20 Lucent Technologies Inc. Self-organizing intelligent network architecture and methodology
AR040693A1 (es) 2002-07-30 2005-04-13 Wyeth Corp Formulaciones parenterales
KR20040015624A (ko) * 2002-08-13 2004-02-19 대한뉴팜(주) 플로르페니콜을 활성성분으로 함유하는 경구투여용약제학적 조성물
GB0218996D0 (en) * 2002-08-14 2002-09-25 Novartis Ag Organic compounds
FR2849055A1 (fr) * 2002-12-18 2004-06-25 Exonhit Therapeutics Sa Nouvelle cible moleculaire de l'angiogenese et utilisations
WO2004062669A1 (en) * 2003-01-16 2004-07-29 Sucampo Ag Use of a macrolide compound for treating dry eye
US7071248B2 (en) * 2003-01-21 2006-07-04 Ashland Licensing And Intellectual Property, Llc Adhesive additives and adhesive compositions containing an adhesive additive
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US20050049209A1 (en) * 2003-08-06 2005-03-03 Chen Andrew Xian Pharmaceutical compositions for delivering macrolides
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US7387788B1 (en) 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
ATE534373T1 (de) 2003-10-10 2011-12-15 Antares Pharma Ipl Ag Transdermale pharmazeutische formulierung zur minimierung von rückständen auf der haut
US8007737B2 (en) * 2004-04-14 2011-08-30 Wyeth Use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
CN100361656C (zh) * 2004-08-27 2008-01-16 石药集团中奇制药技术（石家庄）有限公司 丁苯酞自乳化释药体系及其制备方法和应用
US8067399B2 (en) 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
KR100699582B1 (ko) 2005-07-11 2007-03-23 삼성전기주식회사 출력 버퍼회로
US20070015693A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7276476B2 (en) * 2005-07-13 2007-10-02 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US7202209B2 (en) 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7501393B2 (en) 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
WO2007059106A2 (en) 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of mntor inhibitor to treat patients with cancer
CN101426475A (zh) * 2006-04-21 2009-05-06 安塔雷斯制药Ipl股份公司 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法
US11975161B2 (en) 2006-11-20 2024-05-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
GB2451811A (en) 2007-08-09 2009-02-18 Ems Sa Delivery composition for solubilising water-insoluble pharmaceutical active ingredients
TW200932240A (en) 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
US9994585B2 (en) * 2007-12-31 2018-06-12 Aphios Corporation Transplantation therapies
ES2645692T3 (es) 2008-11-11 2017-12-07 The Board Of Regents,The University Of Texas System Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
EP2308468A1 (de) * 2009-10-08 2011-04-13 Novaliq GmbH Neuartige pharmazeutische Zusammensetzung mit einem Makrolid-Immunosuppressivum
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
EP2550030B1 (de) * 2010-03-25 2018-04-25 Lutonix, Inc. Wirkstofffreisetzende beschichtungen für medizinische vorrichtungen
CA2798739A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
EA201390660A1 (ru) 2010-11-05 2013-11-29 Селекта Байосайенсиз, Инк. Модифицированные никотиновые соединения и связанные способы
WO2014036654A1 (en) * 2012-09-06 2014-03-13 Mcmaster University Compounds and methods for selectively targeting cancer stem cells
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
EP3089737B1 (de) 2013-12-31 2021-11-03 Rapamycin Holdings, LLC Orale rapamycinnanopartikelzubereitungen und verwendung
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
JP6880136B2 (ja) * 2019-09-27 2021-06-02 ルトニックス，インコーポレーテッド 医療用具のための薬物放出コーティング

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3097135A (en) * 1960-02-04 1963-07-09 Abbott Lab Erythromycin suspensions and method of stabilizing the same
GB1322306A (en) * 1971-04-15 1973-07-04 Meiji Seika Co Stabilized antibiotic preparation and manufacturing process therefor
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
DE2907460A1 (de) * 1978-03-07 1979-09-13 Sandoz Ag Neue resorbierbare galenische kompositionen
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
BE895724A (fr) 1982-02-01 1983-07-28 Sandoz Sa Nouvelle utilisation therapeutique de la dihydrocyclosporine d
JPS60133882A (ja) * 1983-12-21 1985-07-17 Nippon Carbide Ind Co Ltd ビタミン類生産性微生物の培養方法
DE3406497A1 (de) * 1984-02-23 1985-09-05 Mueller Bernhard Willi Werner Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung
US4678807A (en) * 1984-03-01 1987-07-07 Baxter Travenol Laboratories, Inc. Method for directed visceral metabolism of medium chain triglycerides
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US4707470A (en) 1985-05-17 1987-11-17 Smithkline Beckman Corporation Polyene antibiotic emulsion formulation
US4831018A (en) * 1985-05-17 1989-05-16 Smithkline Beckman Corporation Polyene antibiotic emulsion formulation
US4678808A (en) * 1985-10-15 1987-07-07 Baxter Travenol Laboratories, Inc. Rapid acting intravenous emulsions of omega-3 fatty acid esters
IL87219A0 (en) * 1987-08-07 1988-12-30 Abbott Lab Erythromycin formulations for oral administration
GB8721376D0 (en) * 1987-09-11 1987-10-21 Glaxo Group Ltd Chemical compounds
HU201567B (en) 1988-07-21 1990-11-28 Gyogyszerkutato Intezet Process for production of intravenous medical compositions containing cyclosphorin
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
ES2052016T3 (es) * 1988-09-29 1994-07-01 Shiseido Co Ltd Composicion emulsionada.
US4987139A (en) * 1989-05-05 1991-01-22 Merck & Co., Inc. FK-520 microbial transformation product
AU630469B2 (en) * 1989-05-26 1992-10-29 Abbott Laboratories Injectable clarithromycin composition
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5215995A (en) * 1989-10-16 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Hair revitalizing agent
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
DK0427680T3 (da) * 1989-11-09 1995-12-18 Sandoz Ltd Heteroatom-holdige cykliske forbindelser
GB8925797D0 (en) * 1989-11-15 1990-01-04 Fisons Plc Compositions
KR0177158B1 (ko) * 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제
JPH05507915A (ja) * 1990-06-11 1993-11-11 藤沢薬品工業株式会社 特発性血小板減少性紫斑病およびバセドウ病治療薬製造のためのｆｋ５０６等のマクロライド化合物の用途
US5190950A (en) * 1990-06-25 1993-03-02 Merck & Co., Inc. Antagonists of immunosuppressive macrolides
ES2118087T3 (es) 1990-08-10 1998-09-16 Anormed Inc Composiciones inmunosupresoras.
PT95230B (pt) 1990-09-06 1997-09-30 Roy Calne Utilizacao de rapamicina e/ou dos seus derivados e/ou dos seus derivados e/ou pre-farmacos na producao de composicoes farmaceuticas para inibicao da rejeicao de transplantes de orgaos ou tecidos em mamiferos.
GB2247620A (en) * 1990-09-07 1992-03-11 Fujisawa Pharmaceutical Co The use of macrolide compounds for cytomegalovirus infection
GB2248184A (en) * 1990-09-28 1992-04-01 Fujisawa Pharmaceutical Co New use of macrolide compounds for active oxygen-mediated diseases
GB2249027A (en) * 1990-10-23 1992-04-29 Fujisawa Pharmaceutical Co Use of macrolide compounds for hepatic failure
PH31204A (en) * 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
GB9103430D0 (en) 1991-02-19 1991-04-03 Smithkline Beecham Plc Novel compound
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
NO921449L (no) 1991-04-17 1992-10-19 American Home Prod Karbamater av rapamycin
MX9201782A (es) 1991-04-19 1992-10-01 Sandoz Ag Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene.
FI97472C (fi) 1991-05-07 1996-12-27 American Home Prod Menetelmä terapeuttisesti käyttökelpoisten rapamysiinijohdannaisten valmistamiseksi anti-inflammatorisina ja antifungaalisina aineina
CA2102116A1 (en) * 1991-05-31 1992-12-01 Gary R. Schulte Use of rapamycin prodrugs as immunosuppressant agents
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
AU667483B2 (en) * 1991-07-26 1996-03-28 Smithkline Beecham Corporation W/O microemulsions
US5169851A (en) * 1991-08-07 1992-12-08 American Home Products Corporation Rapamycin analog as immunosuppressants and antifungals
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5221740A (en) 1992-01-16 1993-06-22 American Home Products Corporation Oxepane isomers of rapamycin useful as immunosuppressive agents
GB9208712D0 (en) * 1992-04-22 1992-06-10 Sandoz Ltd Pharmaceutical compositions containing cyclosporin derivates
US5527537A (en) * 1992-05-18 1996-06-18 Dietl; Hans Pharmaceutical preparation containing cyclosporine(s) for intravenous administration and a process for its production
PT589843E (pt) * 1992-09-25 2002-04-29 Novartis Ag Composicoes farmaceuticas contendo ciclosporinas
US5318895A (en) * 1992-10-05 1994-06-07 Merck & Co., Inc. Aspergillus niger mutants
JPH06183970A (ja) 1992-12-16 1994-07-05 Fujisawa Pharmaceut Co Ltd 医薬用組成物
JPH08507788A (ja) * 1993-03-17 1996-08-20 アボツト・ラボラトリーズ 置換脂環式アミン含有大環状免疫調節剤
US5622714A (en) * 1993-05-12 1997-04-22 Dietl; Hans Pharmaceutical preparation containing cyclosporine(s) for intravenous administration and process for its production
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
DE4322826A1 (de) 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat
DE4329503A1 (de) 1993-09-01 1995-03-02 Galenik Labor Freiburg Gmbh Pharmazeutische Präparate zur gezielten Behandlung von Morbus Crohn und Colitis Ulcerosa
AU688782B2 (en) 1993-09-30 1998-03-19 Wyeth Rapamycin formulations for oral administration
IL111003A0 (en) 1993-09-30 1994-11-28 American Home Prod Multi-component oral rapamycin formulation
IL111004A (en) 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5536729A (en) 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5516770A (en) 1993-09-30 1996-05-14 American Home Products Corporation Rapamycin formulation for IV injection
IL129547A (en) 1994-10-26 2001-01-11 Novartis Ag Pharmaceutical compositions comprising a macrolide and an acid
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
JP3934705B2 (ja) 1995-05-26 2007-06-20 ノバルティス ファーマ株式会社 サイクロデキストリン組成物
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
CA2230748C (en) 1997-03-14 2010-08-03 American Home Products Corporation Rapamycin formulations for oral administration
CA2293793C (en) 1997-06-13 2006-07-11 American Home Products Corporation Rapamycin formulations for oral administration

Also Published As

Publication number Publication date
JP3121203B2 (ja) 2000-12-25
JP2007039471A (ja) 2007-02-15
JP3933339B2 (ja) 2007-06-20
US5932243A (en) 1999-08-03
ITRM940324A0 (it) 1994-05-24
ES2098180B1 (es) 1998-07-01
ES2098180A1 (es) 1997-04-16
US6565859B1 (en) 2003-05-20
HK1011278A1 (en) 1999-07-09
JP4709729B2 (ja) 2011-06-22
DE4418115B4 (de) 2009-07-23
US7025975B2 (en) 2006-04-11
BE1008329A3 (fr) 1996-04-02
JPH11315022A (ja) 1999-11-16
US20040209911A1 (en) 2004-10-21
US20030166517A1 (en) 2003-09-04
IT1272992B (it) 1997-07-01
JPH07138161A (ja) 1995-05-30
AT408521B (de) 2001-12-27
FR2705566A1 (fr) 1994-12-02
DE4418115A1 (de) 1994-12-01
ITRM940324A1 (it) 1995-11-24
CA2124259C (en) 2012-01-10
CA2124259A1 (en) 1994-11-28
FR2705566B1 (fr) 1996-04-05
CH686761A5 (de) 1996-06-28

Similar Documents

Publication Publication Date Title
ATA106594A (de) Pharmazeutische orale zusammensetzung enthaltend verbindungen der rapamycinklasse
ATA129892A (de) Pharmazeutische zusammensetzung
DE69634053D1 (de) Oral anzuwendende Arzneizusammensetzung enthaltend 2-Methyl-thienobenzodiazepin
ATE207468T1 (de) Aromatische verbindungen und diese enthaltende pharmazeutische zusammenstellungen
DE4291156T1 (de) Verbesserte pharmazeutische Zusammensetzungen
DE69816471D1 (de) Pyrimidinon verbindungen und diese enthaltende pharmazeutische zusammenstellungen
PT589843E (pt) Composicoes farmaceuticas contendo ciclosporinas
DK0747050T3 (da) Farmaceutiske sammensætninger indeholdende irbesartan
FI981777A7 (fi) Farmaseuttinen ainekoostumus
FI922316L (fi) Farmaceutisk sammansaettning
IL111007A0 (en) Composition containing rapamycin for oral administration
DE59712959D1 (de) Orale pharmazeutische zubereitung enthaltend ibandronat
FI973518L (fi) Farmaseuttinen koostumus piperidinoalkanoliyhdisteille
DE69621885D1 (de) Neue galenische orale pharmazeutische formulierung
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
DE69101931D1 (de) Pharmazeutische Zusammensetzung.
ATE211132T1 (de) Aromatische verbindungen und diese enthaltende pharmazeutische zusammenstellungen
DE69133371D1 (de) Pharmazeutische wirksame Benzochinazolin Verbindungen
IT1231012B (it) Composizione farmaceutica per uso orale contenente nac.
ITMI921123A0 (it) Formulazioni farmaceutiche orali contenenti antocianosidi
FI944534A7 (fi) Rapamysiinikoostumuksia oraalisesti annettaviksi
ATE216238T1 (de) Arzneimittel enthaltend lipidsenkende verbindungen
FI944535L (fi) Rapamysiinikoostumuksia oraalisesti annettaviksi
DE4294862T1 (de) Pharmazeutische Komposition
FI910088A7 (fi) Oraalinen farmaseuttinen koostumus

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
MM01 Lapse because of not paying annual fees

Effective date: 20120515